One-Year treatment trial aims to control blood cancer without lifelong drugs
NCT ID NCT06333262
Summary
This study is testing a one-year treatment plan for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants will take the drug pirtobrutinib for six months, then add obinutuzumab for another six months, after which all treatment stops. The goal is to see if this fixed-duration approach can effectively control the cancer, potentially allowing patients to live without continuous medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
-
Brigham & Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
New England Cancer Specialists
RECRUITINGScarborough, Maine, 04074, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.